
Combining osimertinib with platinum-based chemotherapy improves progression-free survival in EGFR-mutated NSCLC.


coremsg

Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.

Osimertinib Plus Chemo Ups PFS, Toxicity in First Line

osimertinib-plus-chemo-improves-pfs-in-first-line-egfr-mutated-nsclc


Osimertinib Plus Chemo Improves PFS in First-Line EGFR-Mutated NSCLC
